2 Martin CL, Albers JW, Pop-Busui R. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial The primary aim was to determine the individual albuminuria-lowering response of four albuminuria-lowering drug classes in persons with type 1 diabetes. Keywords: clinical trial; diabetes complications; diabetic neuropathy; empagliflozin; linagliptin; SGLT2 inhibitor EN clinical trial diabetes complications diabetic neuropathy empagliflozin linagliptin SGLT2 inhibitor 3064 3067 4 09/06/23 20231001 NES 231001 INTRODUCTION Cardiovascular autonomic neuropathy (CAN) is a prevalent complication in type 1 diabetes and a risk factor for cardiovascular mortality.[1] CAN is preventable to some extent: Intensive glucose control demonstrated a 45% risk reduction of CAN in persons with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC).[2] To our knowledge, however, no treatment is available when CAN is incident. [Extracted from the article]